T50 - one target for multiple treatments

 


We are working to improve health and disease management of patients worldwide

 

CALCISCON's patented T50 test is an improved proxy for phosphate toxicity. Our scalable test kit and data analysis software are already approved in Europe (CE).

Our breakthrough innovation provides a new unifying treatment target for chronic kidney disease patients and has large market potential. 


We are currently raising a series A round. 


Please contact for further information:

Andreas Pasch, andreas.pasch@calciscon.com or

Vincent Linder, vincent.linder@calciscon.com



 

 

Calciscon is supported by: